Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Value · Kirr Marbach Partners

Kirr, Marbach Partners Value Fund (KMVAX)

Ticker KMVAX · · Holdings as of Jun 30, 2026

Expense ratio
1.35%$135/yr per $10k
5-yr return
+13.8%annualized
1-yr return
+14.4%as of Dec 2025
Net assets
$115.6Mall share classes
Holdings
40

Bottom line

Is KMVAX a good fund? The bottom line

KMVAX is a managed large value mutual fund from Kirr Marbach Partners.

Its expense ratio is 1.35% — about $135 a year on every $10,000 invested, more expensive than 85% of large value funds we track.

It returned +14.4% over one year, +13.8% a year over five years, +9.9% a year over ten (as of Dec 31, 2025, per its prospectus).

With $116 million in net assets and 40 holdings, its largest position is MasTec Inc (10.8%) and the top 10 make up 54.2% of the portfolio.

What stands out

  • 5-year return beat 90% of category peers

What to watch

  • Expensive for its category (1.35%)
  • Concentrated: top 10 holdings are 54.2% of assets
  • 12b-1 marketing fee of 0.07% a year

Updated Nov 19, 2026

What KMVAX invests in

The Fund's investment objective is long-term capital growth.

The Fund seeks to achieve its investment objective by investing in common stocks of companies with small-capitalizations (less than $1 billion), medium-capitalizations ($1-$15 billion) and large-capitalizations (more than $15 billion). Under normal circumstances, at least 65% of the Fund's total assets will consist of common stocks or other equity securities. The Adviser generally follows a value approach to investing for the Fund. Accordingly, the Fund will focus on securities of companies that the Adviser believes are undervalued relative to their intrinsic worth and possess certain characteristics that the Adviser believes will lead to a higher market price over time.

From the fund's prospectus (filed Jan 28, 2026).

KMVAX performance

Fund calendar-year total returns, 2016–2025 2016: +10.8%; 2017: +16.1%; 2018: −19.6%; 2019: +27.0%; 2020: +2.9%; 2021: +28.8%; 2022: −16.0%; 2023: +20.4%; 2024: +27.9%; 2025: +14.4% +11% 2016 +16% 2017 −20% 2018 +27% 2019 +3% 2020 +29% 2021 −16% 2022 +20% 2023 +28% 2024 +14% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
KMVAX+14.4%+13.8%+9.9%
Large Value median+13.6%+11.3%+10.2%

Source: Fund prospectus, as of Dec 31, 2025

Full KMVAX performance history →

What KMVAX costs

On a $10,000 investment, KMVAX's 1.35% expense ratio costs about $135 a year. The prospectus estimates $1,577 in total costs over 10 years (assuming 5% annual returns). The median large value fund charges 0.81%.

See the full KMVAX fee table →

KMVAX top 10 holdings

#Holding% of fund
1MasTec Inc MTZ10.76%
2EMCOR Group Inc EME8.55%
3Broadcom Inc AVGO6.49%
4Alphabet Inc GOOGL5.97%
5Vistra Corp VST4.58%
6Moog Inc MOG/A4.03%
7AutoZone Inc AZO3.90%
8Generac Holdings Inc GNRC3.80%
9Republic Services Inc RSG3.05%
10Markel Group Inc MKL3.03%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 54.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to KMVAX

More funds like KMVAX →

KMVAX FAQ

What is the expense ratio of KMVAX?
KMVAX's expense ratio is 1.35%, which works out to about $135 a year for every $10,000 invested. The prospectus estimates total costs of $1,577 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is KMVAX a good investment?
It depends on your goals, but the data points to: 5-year return beat 90% of category peers; expensive for its category (1.35%); concentrated: top 10 holdings are 54.2% of assets; 12b-1 marketing fee of 0.07% a year. This is general information, not personalized advice.
What does KMVAX hold?
KMVAX's largest holdings are MasTec Inc (10.8%), EMCOR Group Inc (8.6%), Broadcom Inc (6.5%), Alphabet Inc (6.0%), Vistra Corp (4.6%). It holds 40 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is KMVAX's 5-year return?
KMVAX returned +13.8% a year over the five years ending Dec 31, 2025, and +9.9% a year over ten years. Past performance does not guarantee future results.
Who manages KMVAX?
KMVAX is offered by Kirr Marbach Partners through Kirr Marbach Partners Funds Inc.